ConvaTec Group PLC (LON:CTEC) Receives Consensus Rating of “Buy” from Brokerages

Shares of ConvaTec Group PLC (LON:CTEC) have earned a consensus recommendation of “Buy” from the six research firms that are currently covering the company, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a buy rating. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is GBX 320.33.

CTEC has been the subject of several analyst reports. Berenberg Bank increased their price objective on ConvaTec Group from GBX 330 to GBX 340 and gave the company a “buy” rating in a report on Thursday, January 22nd. Peel Hunt reaffirmed an “add” rating and set a GBX 270 target price on shares of ConvaTec Group in a research report on Thursday, November 13th. UBS Group reissued a “buy” rating and issued a GBX 375 price target on shares of ConvaTec Group in a report on Friday, November 7th. Finally, JPMorgan Chase & Co. restated an “overweight” rating on shares of ConvaTec Group in a report on Friday, November 14th.

ConvaTec Group Price Performance

LON CTEC opened at GBX 227.43 on Friday. The company has a market cap of £4.43 billion, a PE ratio of 21.46, a price-to-earnings-growth ratio of 0.93 and a beta of 0.64. ConvaTec Group has a 52 week low of GBX 209.40 and a 52 week high of GBX 311.20. The company has a quick ratio of 0.96, a current ratio of 2.26 and a debt-to-equity ratio of 85.32. The firm’s 50-day simple moving average is GBX 234.18 and its two-hundred day simple moving average is GBX 235.55.

About ConvaTec Group

ConvaTec Group PLC engages in the development, manufacturing, and sale of medical products, services, and technologies in Europe, North America, and internationally. The company offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, and bladder cancer.